Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Dong-A Regains Top Spot From Green Cross In Q2 Sales

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Dong-A Pharmaceutical regained South Korea's top sales spot in the second quarter from vaccine maker Green Cross and expects to continue its sales trend through the year
Advertisement

Related Content

LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma
LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma
South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment
Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products
Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
Advertisement
UsernamePublicRestriction

Register

SC075846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel